title: Current status of antibody therapy for breast cancer.
abstract: Antibody therapy with trastuzumab has greatly impacted breast cancer treatment. Combination treatment with trastuzumab is regarded currently as a first-line therapy for metastatic breast cancers that overexpress Her-2. It has become routine practice to examine the status of Her-2 expression in primary tumors. The impact of this therapy might be as great as that of endocrine therapy from a historical point of view. A number of new approaches using trastuzumab for seeking individualized treatment are being tested in current clinical trials. We reviewed recent advances in trastuzumab treatment and discuss the future of antibody therapy for breast cancer.
authors.affiliation: Department of Surgery, Tokyo Metropolitan Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan. maktoi77@wa2.so-net.ne.jp
authors.forename: Masakazu
authors.initials: M
authors.lastname: Toi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Takada
authors.forename: Hiroko
authors.initials: H
authors.lastname: Bando
authors.forename: Kazumi
authors.initials: K
authors.lastname: Toyama
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Yamashiro
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Horiguchi
authors.forename: Shigehira
authors.initials: S
authors.lastname: Saji
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D005260:Female; D018734:Genes, erbB-2 / Q000235:genetics; D006801:Humans; D009362:Neoplasm Metastasis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000187:drug effects / Q000235:genetics; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab